KOD (Kodiak Sciences Inc Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by KOD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | JOHN A. BORGESON | Chief Financial Officer | A | — | — |
| 2026-07-17 | VICTOR PERLROTH | Chairman and CEO | A | — | — |
| 2026-07-02 | Richard S Levy | Director | A | — | — |
| 2026-07-02 | Taiyin Yang | Director | A | — | — |
| 2026-07-02 | Bassil I Dahiyat | Director | A | — | — |
| 2026-07-02 | Charles A Bancroft | Director | A | — | — |
| 2026-07-02 | ROBERT PROFUSEK | Director | A | — | — |
| 2026-07-02 | BAKER BROS. ADVISORS LP | Director | A | — | — |
| 2026-06-05 | JOHN A. BORGESON | Chief Financial Officer | MIXED | — | — |
| 2026-04-16 | JOHN A. BORGESON | Chief Financial Officer | M | — | — |
| 2026-04-02 | JOHN A. BORGESON | Chief Financial Officer | MIXED | — | — |
| 2026-03-27 | VICTOR PERLROTH | Chairman and CEO | M | — | — |
| 2026-03-19 | VICTOR PERLROTH | Chairman and CEO | A | — | — |
| 2025-12-19 | 667, L.P. | Director | Buy | — | — |
| 2025-07-08 | VICTOR PERLROTH | Chairman and CEO | A | — | — |
| 2025-07-08 | JOHN A. BORGESON | See Remarks | A | — | — |
| 2025-07-02 | Bassil I Dahiyat | Director | A | — | — |
| 2025-07-02 | ROBERT PROFUSEK | Director | A | — | — |
| 2025-07-02 | Charles A Bancroft | Director | A | — | — |
| 2025-07-02 | Richard S Levy | Director | A | — | — |
| 2025-07-02 | Taiyin Yang | Director | A | — | — |
| 2025-07-02 | Baker Bros. Advisors (GP) LLC | Director | A | — | — |
| 2025-06-17 | JOHN A. BORGESON | See Remarks | MIXED | — | — |
| 2024-08-07 | JOHN A. BORGESON | See Remarks | A | — | — |
| 2024-08-07 | VICTOR PERLROTH | Chairman and CEO | A | — | — |
| 2024-07-02 | BAKER BROS. ADVISORS LP | Director | A | — | — |
| 2024-07-01 | Taiyin Yang | Director | A | — | — |
| 2024-07-01 | ROBERT PROFUSEK | Director | A | — | — |
| 2024-07-01 | Richard S Levy | Director | A | — | — |
| 2024-07-01 | Charles A Bancroft | Director | A | — | — |
| 2024-07-01 | Bassil I Dahiyat | Director | A | — | — |
| 2024-06-18 | JOHN A. BORGESON | See Remarks | MIXED | — | — |
| 2024-06-13 | JOHN A. BORGESON | See Remarks | MIXED | — | — |
| 2023-07-05 | 667, L.P. | Director | A | — | — |
| 2023-07-03 | Richard S Levy | Director | A | — | — |
| 2023-07-03 | Charles A Bancroft | Director | A | — | — |
| 2023-07-03 | Taiyin Yang | Director | A | — | — |
| 2023-07-03 | ROBERT PROFUSEK | Director | A | — | — |
| 2023-07-03 | Bassil I Dahiyat | Director | A | — | — |
| 2023-06-27 | JOHN A. BORGESON | See Remarks | A | — | — |
| 2023-06-27 | VICTOR PERLROTH | Chairman and CEO | A | — | — |
| 2023-06-27 | JASON EHRLICH | See Remarks | A | — | — |
| 2023-06-16 | JOHN A. BORGESON | See Remarks | MIXED | — | — |
| 2023-06-16 | JASON EHRLICH | See Remarks | MIXED | — | — |
| 2023-06-13 | JASON EHRLICH | See Remarks | M | — | — |
| 2023-06-13 | JOHN A. BORGESON | See Remarks | M | — | — |
| 2022-07-08 | JOHN A. BORGESON | See Remarks | A | — | — |
| 2022-07-08 | VICTOR PERLROTH | Chairman and CEO | A | — | — |
| 2022-07-08 | JASON EHRLICH | See Remarks | A | — | — |
| 2022-07-05 | Charles A Bancroft | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 18,358,772 | — |
| — | Director | 15,604,214 | — |
| — | Director | 15,316,021 | — |
| — | Director | 15,142,074 | — |
| — | Director | 14,393,675 | — |
| — | Chairman and CEO | 2,451,718 | — |
| — | Director | 1,143,396 | — |
| — | Chief Financial Officer | 211,930 | — |
| — | SVP, Discovery Medicine | 130,166 | — |
| — | See Remarks | 64,182 | — |
| — | Director | 10,000 | — |
| — | Director | 250 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KOD quote page; the site-wide leaderboard is on the insider transactions hub.